Monitoring Requirements for Telehealth Ketamine

The absence of in-room clinical supervision is the most significant safety tradeoff of at-home ketamine compared to in-person IV infusion. Reputable telehealth programs compensate for this gap with systematic safety protocols that, while not equivalent to in-room supervision, provide meaningful safety infrastructure. This guide describes what good monitoring looks like.

Pre-Session Monitoring

Vital Sign Assessment

Before every session, patients at responsible telehealth programs take and record their:

• Blood pressure: Both systolic and diastolic readings
• Heart rate: Resting pulse
• Oxygen saturation: Via pulse oximeter

These readings are reported to the provider or entered into the platform before the session begins. Providers establish individualized thresholds—typically:

• Hold the session if systolic BP > 160-180 mmHg
• Hold if resting heart rate > 100-110 bpm
• Hold if O2 saturation < 95%

Documenting pre-session vitals creates a longitudinal record. Trends—such as progressively elevated blood pressure across sessions—can identify emerging cardiovascular risk before it becomes a serious problem.

Symptom and Mood Check-In

Before each session, patients typically complete a brief standardized check-in asking about:

• Current mood state
• Presence of recent unusual symptoms
• Use of any medications, alcohol, or substances in the past 24 hours
• Whether a sitter is present

This check-in both screens for acute safety concerns and provides data for outcomes tracking.

PDMP Confirmation (For Providers)

Behind the scenes, responsible providers confirm that the patient is not receiving controlled substance prescriptions from other providers simultaneously. PDMP checks are a required part of responsible prescribing, not optional.

During-Session Monitoring

Live Video Monitoring

Some platforms require live video monitoring throughout sessions—a provider or care guide maintains a video connection and checks in periodically during the session. This is the highest standard of during-session monitoring in the at-home model and is closest to having a person in the room.

However, live video monitoring is not universal. Some platforms do not require it, or make it optional. Ask your provider: is someone watching a live video feed during my session, or are they simply available by phone?

Sitter Presence

Most responsible programs require a sober adult sitter to be physically present, particularly for the first several sessions. The sitter is not a trained clinician (see our support systems guide for sitter details) but serves as:

• A grounding presence
• The person who calls for help if something goes wrong
• The person who monitors the patient for obvious signs of distress

Sitter requirements vary: some platforms require a sitter for all sessions; others require one only for the first 1-3 sessions; some "strongly recommend" rather than require a sitter.

Emergency Contact Verification

Before each session, providers should confirm that the patient has emergency contact information accessible—the provider's emergency line, the sitter's phone, and 911.

Blood Pressure During Sessions

Some programs ask patients to take a blood pressure reading during the session (when the effects are near peak) as well as before. This requires a sitter or the patient themselves to take readings mid-session—challenging when significantly impaired, but provides important data.

Post-Session Monitoring

Same-Day Check-In

A post-session check-in—ideally within 2 hours of the session ending—is a standard component of responsible programs. This can be:

• A scheduled video call with a care guide
• A secure message exchange
• An app-based brief questionnaire

The post-session check-in confirms: the patient has returned to baseline, no adverse events occurred, and the patient is safe to be without supervision.

Vital Signs Post-Session

Post-session blood pressure and heart rate readings provide data on how quickly cardiovascular effects resolve and whether they are within acceptable ranges.

Symptom and Integration Tracking

Beyond acute safety monitoring, post-session outcomes tracking (PHQ-9, GAD-7, or similar instruments administered at regular intervals) provides the clinical data needed to:

• Assess whether the treatment is working
• Identify patients who are not responding and need a different approach
• Detect early signs of adverse psychological effects (increased anxiety, destabilization, cognitive changes)

Long-Term Monitoring

Scheduled Provider Appointments

Responsible programs schedule regular clinical appointments (monthly or quarterly) for:

• Comprehensive symptom reassessment with validated scales
• Review of blood pressure trend data
• Assessment of urinary symptoms (long-term ketamine use risk)
• Cognitive function self-report (memory, concentration)
• Discussion of integration progress and maintenance planning
• Re-evaluation of the clinical rationale for continued treatment

Hepatic Function

For patients receiving ketamine on an ongoing maintenance basis (more than 3-4 months continuously), liver function tests (LFTs) should be checked periodically. The schedule varies by provider and patient risk factors, but quarterly or biannual LFTs are reasonable for ongoing maintenance patients.

Urology Monitoring

Long-term ketamine use is associated with urinary tract problems in some patients. Providers should ask at every follow-up about urinary symptoms: urgency, frequency, pain on urination. Patients who develop urinary symptoms should be evaluated promptly.

What to Ask About Monitoring When Evaluating Platforms

• "Who monitors me during a session, and how—live video, phone availability, or neither?"
• "Is a sitter required for my first session? For all sessions?"
• "What vital sign measurements are required before sessions, and what are the thresholds for proceeding?"
• "How do I report adverse events between scheduled appointments?"
• "What is the protocol if you lose video contact with me during a session?"
• "How often do you check liver function in ongoing patients?"
• "What are the long-term monitoring requirements if I continue treatment beyond 6 months?"

Platforms that can answer these questions clearly and specifically have thought seriously about monitoring. For a broader evaluation framework, see what to look for in a telehealth ketamine provider. Platforms that are vague, inconsistent, or unable to answer are likely providing less rigorous safety oversight than the standard of care requires.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service